# About Telehealth TB-500: An Independent Research Digest | TB-500

> Telehealth TB-500 is an independent editorial project publishing cited summaries of the TB-500 and thymosin beta-4 research literature. Not a clinic, not a vendor, not a prescriber.

An independent editorial digest of the published TB-500 and thymosin beta-4 research record — built to keep the fragment honest against the protein, and to state the regulatory standing plainly.

## What this site is

Telehealth TB-500 is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent protein, thymosin beta-4. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "telehealth" in the name is editorial framing — a position this publisher occupies relative to the medicinal-access conversation around peptides, not a claim that the site offers consultation, prescription, or treatment services. It does not. The site has one job: read the literature carefully and cite it.

## How we read the evidence

Two editorial rules shape every page. First, the fragment-versus-full-length distinction is kept in plain sight. TB-500 is the seven-residue Ac-LKKTETQ fragment of a 43-residue protein, and most published efficacy data were generated with the full protein [5]. Where a finding used full-length thymosin beta-4, we say so rather than letting the parent protein's record stand in for the fragment's.

Second, the gaps are stated as findings. There are no completed controlled clinical trials of the TB-500 heptapeptide for any indication [4], and the empty human-evidence column is reported as plainly as the positive animal results. Every quantitative claim — every dose, percentage, and tolerability figure — maps to a numbered source on the references page. Regulatory statements are drawn from FDA primary sources and stated present-tense; we do not present any future FDA action as decided.

## What this site is not

This is not a place to buy anything, and it is not a substitute for a licensed prescriber. We name no vendors, pharmacies, clinics, or telehealth providers, and we give no human dosing. The dose figures here describe what was administered to which species at which dose by which route in published studies — a research record, not instructions.

If you are evaluating compounded-medication access, the [TB-500 legal status](/legal-status) page describes the lawful pathway in general terms and the FDA 503A standing as it stands. For anything specific to your situation, that is a conversation for an appropriately licensed professional, not for this site.

---

A risograph reading of the TB-500 record, where the Ac-LKKTETQ fragment overlaps its parent protein thymosin beta-4 the way two inks overlap on the page — each finding plated to its study, the human-evidence panel left blank, and the FDA 503A standing printed first; no clinic behind the press and nothing here dispensed or sold.